What is Meliora?
Founded in 2021 and headquartered in Menlo Park, CA, Meliora is a biotechnology company dedicated to advancing oncology drug development. The company's strategic focus on cancer therapeutics positions it within a critical and rapidly evolving sector of the pharmaceutical industry. Meliora aims to leverage its scientific expertise and recent capital infusion to bring novel treatments to patients.
How much funding has Meliora raised?
Meliora has raised a total of $11M across 1 funding round:
Angel/Seed
$11M
Angel/Seed (2022): $11M with participation from ZhenFund, Village Global, BrightEdge, Pebblebed, Obvious Ventures, and HOF Capital
Key Investors in Meliora
ZhenFund
ZhenFund is an angel investment firm that supports young, tech-savvy founders with quick decision-making and a commitment to collaboration, focusing on innovation and risk-taking.
Village Global
Village Global VC is an early-stage venture capital firm that invests between $500K and $3M in pre-seed and seed rounds globally, supporting resourceful founders across various sectors.
BrightEdge
BrightEdge is an enterprise SEO marketing company that transforms online content into tangible business results using an AI and machine learning engine for web-wide, real-time measurement of digital content engagement.
What's next for Meliora?
With a substantial enterprise-level funding context and a recent strategic investment, Meliora is poised for accelerated growth and innovation. The company is likely to expand its research pipeline, potentially initiate new clinical trials, and scale its operational capacity. This strategic backing suggests confidence from investors in Meliora's long-term vision and its potential to make a significant impact in the field of oncology.
See full Meliora company page
